A Phase 1 interventional study of intranasal oxytocin and oral probiotics in Autism Spectrum Disorder, sponsored by Massachusetts General Hospital. Completed at 1 site in United States. Open to participants aged 3 Years to 25 Years. Per ClinicalTrials.gov, last updated 2020-03-04.
Sponsored by Massachusetts General Hospital · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 37 studies in Autism Spectrum Disorder by Massachusetts General Hospital — 3 open to participants now, 4 under way, none of them phase 3. Autism Spectrum Disorder · Massachusetts General Hospital.
Among the 37 studies in Autism Spectrum Disorder by Massachusetts General Hospital, this one is the 12th largest by enrollment of the 27 interventional ones that give a count, is one of 4 that started in 2018, is the only one in phase 1, and was the 23rd registered.
1,732 studies on the registry are indexed under Autism Spectrum Disorder; 504 are open to participants now.
Browse Autism Spectrum Disorder studies →3 of the 37 studies in Autism Spectrum Disorder by Massachusetts General Hospital are open now, in 1 country. Recruiting first, the newest first:
Massachusetts General Hospital · Sites in United States
Ages 12–17
Massachusetts General Hospital · Sites in United States
Ages 7–17
Massachusetts General Hospital · Sites in United States
Ages 18–60
By country, each count listing its studies:
Of the 350 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 295 (84%) stop at 75 or younger; 299 take children under 18; 92 take healthy volunteers.
This study: 3 Years to 25 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
37 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 35 is below the median of 52 across 1,373 interventional studies indexed under Autism Spectrum Disorder.
Median enrollment 30 across the 27 interventional studies, 45 across the 10 observational. Of the 31 that completed or were terminated, 16 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
Massachusetts General Hospital is the lead sponsor of 2,591 studies on the registry; 446 are open to participants now.
Of its 224 completed or terminated interventional studies of FDA-regulated products, 168 (75%) have results posted.
1 of the studies in Autism Spectrum Disorder by Massachusetts General Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03827941Massachusetts General HospitalAuricular Transcutaneous Electrical Nerve Stimulation Treatment of Autism | 2027-09-28 |
Add it to your calendar (.ics) → With an account.
Among the 37 studies in Autism Spectrum Disorder by Massachusetts General Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Because oral probiotics reported to potentially induce endogenous Oxytocin, and Oxytocin has been reported to improve social behaviors, the investigators will conduct a pilot trial to compare the effects of probiotics and Oxytocin on social behavioral changes in ASD children. Additionally, the investigators will check oxytocin levels, and perform brain fMRI in some subjects, in order to determine which treatment is more efficient, sustainable, and practical, and whether both treatments in combination are better than either treatment alone. If the trial is conclusive, the investigators will conduct a trial in large scale to understand more the mechanism of ASD behaviors and corresponding effective interventions.
This study description is in accordance with the Consolidated Standards of Reporting Trials (CONSORT) guidelines that are published for the evaluation of randomized controlled trials. This clinical trial is a randomized, double-blind placebo controlled study. Subjects will be randomized to 2 groups:
Phase 1: a. oral placebo, and b. oral probiotics; Phase 2: a. intranasal Oxytocin(OXT) + oral placebo, and b. intranasal OXT + oral probiotics
The treatment will proceed for a total of 28 weeks. In the first phase (16 weeks), all the patients will be randomly and proportionally divided into two groups: Group A (30 subjects) receives oral probiotics while Group B (30 subjects) receives an oral placebo. In the second phase, subjects in Group A and Group B will continue their respective oral probiotics or placebo administration as in Phase 1. In addition, both groups will be simultaneously administered with intranasal OXT spray.
Testing will be performed 3 times total (before, during, and after treatment). The tests include behavioral surveys, cognitive tests, clinical autonomic tests, and blood tests for oxytocin levels. Investigators plan to select up to 10 subjects from each group to conduct a series of MRI studies at week 0, week 16 and week 28.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive oral probiotics, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
Drug: intranasal oxytocin · Dietary Supplement: oral probiotics
Subjects will receive oral placebo, 2 pills per day, for 28 weeks. For the last 12 weeks, subjects will also receive intranasal oxytocin spray at the following dose: 4 IU in week 1, 8 IU in week 2, 16 IU in week 3, and 24 IU in weeks 4-12.
Drug: intranasal oxytocin · Dietary Supplement: oral placebo
4-24 IU per day, dosage gradually increases
Also known as: Novartis Syntocinon
200 million cfu per day
2 pills per day
Social Responsiveness Scale (SRS) Edition 2
social communication and behavior - The scoring is based on T-score which is based on the sum of responses as follows (76 to higher - severe, 66 to 75- moderate deficiencies, 60 to 65 - mild deficiencies, 59 and below is not clinically significant for ASD).
Time frame: change from baseline at 0, 16, and 28 weeks
Aberrant Behavior Checklist (ABC) Edition 2
social behavior test - The total score is calculated based on 5 sub-scales (Irritability, Social Withdrawal, Stereotypic Behavior, Hyperactive/Noncompliance, and Inappropriate Speech). There are 58 questions that are scored on a 0-3 scale 0 -"not at all a problem", 1- "the behavior is a problem but slight in degree", 2- "the problem is moderately serious" and 3- "the problem is severe in degree". Based on this sub-scores are calculated and added to get the total score.
Time frame: change from baseline at 0, 16, and 28 weeks
Neuroinflammation and Oxytocin levels
neuroendocrine biomarker measured in blood ( Melatonin, Oxytocin, Tumour Necrosis Factor alpha, testosterone and Interleukin 6)
Time frame: change from baseline at 0, 16, and 28 weeks
structural MRI
The software Freesurfer will be used to calculate volume of brain regions and diffusion parameters (e.g. fractional anisotropy and mean diffusivity) from structural T1 and diffusion tensor images respectively. T-tests will be applied for group comparisons.
Time frame: change from baseline at 0, 16, and 28 weeks
Functional MRI (resting state)
Correlation analysis will be used to calculate the connectivity across different brain regions. T-tests will be used for group comparisons.
Time frame: change from baseline at 0, 16, and 28 weeks
Functional MRI (task based)
General linear modeling will be used to calculate brain responses to the tasks. T-tests will be used for group comparisons.
Time frame: change from baseline at 0, 16, and 28 weeks
Autonomic indices 1
Blood volume pulse
Time frame: change from baseline at 0, 16, and 28 weeks
Autonomic indices 2
heart rate
Time frame: change from baseline at 0, 16, and 28 weeks
Autonomic indices 3
peripheral skin temperature
Time frame: change from baseline at 0, 16, and 28 weeks
Autonomic indices 4
skin electrodermal activity
Time frame: change from baseline at 0, 16, and 28 weeks
Autonomic indices 5
blood oxygen saturation
Time frame: change from baseline at 0, 16, and 28 weeks
Microbiome
16s metagenomic sequencing of the microbiome
Time frame: change from baseline at 0, 16, and 28 weeks
Eye tracking and Behavioral task (joint attention)
joint attention - Conduct T-tests and calculate P values for total and average fixation values for each area of interest
Time frame: change from baseline at 0, 16, and 28 weeks
Eye tracking and behavioral task (emotion response)
emotion response - The accuracy and reaction time will be calculated for each time point. Then an ANOVA will be used to compare the results.
Time frame: change from baseline at 0, 16, and 28 weeks
Eye tracking and behavioral task (eye behavior)
eye behavior - Conduct T-tests and calculate P values for total and average fixation values for each area of interest
Time frame: change from baseline at 0, 16, and 28 weeks
Plan to share: No — There is no plan to share data with researchers not involved in this study.
Ran from Dec 2018 to primary completion in Oct 2019, 10 months.
Of 35 phase 1 interventional studies under Autism Spectrum Disorder, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 27. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Massachusetts General Hospital →